ARTICLE | Clinical News
Emixustat: Ph IIa started
February 1, 2017 9:43 PM UTC
Kubota’s Acucela Inc. subsidiary began a blinded, U.S. Phase IIa trial to evaluate 2.5, 5 and 10 mg oral emixustat once daily for 1 month in about 30 patients....
BCIQ Company Profiles
BCIQ Target Profiles